Latest Oligodendroglioma Stories

PORTSMOUTH, N.H., Dec. 2, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields)(TM) device, NovoTTF-100A System(TM), for the treatment of recurrent glioblastoma multiforme (GBM). GBM is a deadly brain tumor affecting approximately 10,000 Americans each year. The NovoTTF(TM) device, approved...

ANAHEIM, Calif., Nov. 21, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that Dr. Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center in Boston, presented follow-up results of a study focusing on overall survival in patients with recurrent glioblastoma multiforme (GBM). The long-term follow-up results from the Phase III EF-11 study compared overall survival at two and three years after initiating therapy in...

Brain tumor specimens taken from neurosurgery cases at the University of California, San Francisco (UCSF) Medical Center has given scientists a new window on the transformation that occurs as healthy brain cells begin to form tumors. The work may help identify new drugs to target oligodendroglioma, a common type of brain tumor, at its earliest stage, when it is generally most treatable. Any potential drugs identified will have to prove safe and effective in clinical trials, a process that...

Study led by St. Jude Children’s Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies The largest study ever of a rare childhood brain tumor found more than half the tumors carried extra copies of specific genes linked to cancer growth, according to research led by St. Jude Children's Research Hospital investigators. The findings identify possible new targets for...

(Ivanhoe Newswire) "“ Scientists have completed a map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings appear to reveal the biological cause of the tumors. Oligodendroglioma accounts for up to 20 percent of brain cancers and more commonly occur in younger people and 30 to 45.To create the map, the scientists sequenced protein-coding genes in seven oligodendroglioma tissue samples, and focused attention on recurring mutations in...

Findings reveal cause of the tumorsJohns Hopkins Kimmel Cancer Center scientists have completed a comprehensive map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings, reported in the Aug. 4 issue of Science, also appear to reveal the biological cause of the tumors, they say.To create the map, the scientists sequenced protein-coding genes in seven oligodendroglioma tissue samples, and focused attention on recurring mutations in two...

CHICAGO, June 6, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced encouraging interim results of a phase II clinical study of OPAXIO (paclitaxel poliglumex, PPX) combined with temozolomide ("TMZ") and radiotherapy ("RT") in patients with newly diagnosed high-grade malignant brain tumors (astrocytomas and glioblastomas). While not a randomized trial, treatment with OPAXIO, TMZ and RT resulted in a median progression free survival (PFS) of 13.5...

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4. (ABSTRACT #6089).The addition of concurrent and adjuvant...

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy. The integration of tumor analysis with the clinical trial and international collaboration, major components of this...

Findings show that damage to surrounding tissue may play role in determining high-grade glioma patients' long-term outcomeMinimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.The researchers found that the occurrence of early side effects, such...